Advertisement
ALGN vs XRAY
Which Stock Would AI Choose? Align Technology (ALGN) vs. Dentsply Sirona (XRAY) Stock Comparison
Key Takeaways
- Align Technology (ALGN) has delivered stronger year-to-date (YTD) performance at approximately 22%, outpacing Dentsply Sirona (XRAY)'s 5% gain amid recent market activity.
- ALGN remains profitable with a price-to-earnings (PE) ratio of around 34, while XRAY reports losses, lacking a meaningful PE ratio.
- ALGN's market capitalization stands at about $13.7 billion, significantly larger than XRAY's $2.4 billion, reflecting scale differences in the dental sector.
- Recent analyst sentiment favors ALGN with price target upgrades, contrasting XRAY's mixed ratings including new sell initiations.
- Both stocks operate in dental health but ALGN benefits from Invisalign growth drivers, while XRAY faces challenges from impairments and revenue pressures.
- Upcoming Q1 2026 earnings for both could influence near-term momentum, with ALGN entering on stronger footing.
Introduction
Align Technology (ALGN) and Dentsply Sirona (XRAY) represent key players in the dental and orthodontic equipment sector, offering investors exposure to innovations in oral care and aligner technology. This comparison analyzes their recent market performance, business dynamics, and relative positioning, aiding traders seeking sector momentum plays and long-term investors evaluating growth potential versus value opportunities in healthcare stocks. With both companies navigating post-pandemic demand shifts and digital advancements, understanding their contrasts helps inform portfolio decisions in a volatile market environment.
ALGN Overview and Recent Performance
Align Technology (ALGN) is a global leader in clear aligner therapy, primarily through its Invisalign system, and intraoral scanners via iTero. The company has demonstrated robust growth in recent quarters, with Q4 2025 revenue up 5.3% year-over-year and earnings per share (EPS) beating estimates. In recent market activity, ALGN shares have surged around 22% YTD, trading near $191 with a market cap exceeding $13 billion. Positive sentiment stems from strong Invisalign case starts, international expansion, and recognition as a top innovator. Analyst upgrades and anticipation for Q1 2026 earnings, expected to show EPS growth, have bolstered momentum despite a beta (volatility measure) of 1.81 indicating higher risk.
XRAY Overview and Recent Performance
Dentsply Sirona (XRAY), a leading provider of dental consumables, equipment, and technology, operates a diversified portfolio including implants and imaging systems. Recent quarters revealed challenges, with Q4 2025 revenue at $961 million but marred by a $144 million non-cash impairment charge and ongoing net losses. Shares hover around $12, with YTD gains of about 5% but a 52-week range showing significant volatility from a high of $17. High debt-to-equity (185%) and negative profit margins have pressured performance. While new digital workflows offer upside, mixed analyst views—including a recent sell initiation—and dividend adjustments have tempered sentiment in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 350 available agents that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions earn a spot among the 25 featured trending bots, displaying impressive stats like annualized returns ranging from 15% to over 167%, win rates of 48% to 88%, and profit factors up to 11.7. These bots employ diverse strategies—such as short-term scalping (5-60 minutes), trend following, or multi-agent systems—with customizable risk parameters like take-profit/stop-loss corridors. Traders can copy signals in real-time, adapting to various timeframes and sectors. Explore these high-performing options to enhance your strategy.
Head-to-Head Comparison
Align Technology (ALGN) focuses on a high-growth niche in orthodontic aligners, driving revenue through recurring Invisalign sales and scanner adoption, contrasting Dentsply Sirona (XRAY)'s broader but slower-growing dental consumables and equipment model. Recent momentum favors ALGN, with superior YTD returns and profitability (10% margins) versus XRAY's losses and impairments. Risk profiles differ: ALGN's higher beta exposes it to market swings, while XRAY grapples with elevated leverage. Sector exposure overlaps in digital dentistry, but ALGN benefits from aesthetic demand catalysts, while XRAY contends with margin pressures. Market sentiment tilts toward ALGN's innovation edge over XRAY's turnaround efforts.
Tickeron AI Verdict
Tickeron’s AI currently leans toward Align Technology (ALGN) over Dentsply Sirona (XRAY), based on consistent upward trends, stronger relative performance, profitability, and positive catalysts like earnings anticipation. While XRAY offers potential value at lower valuations, its stability lags, making ALGN the probabilistically favored pick in the current dental sector landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Buy and XRAY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- XRAY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 3 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).
- ALGN’s TA Score: 3 bullish, 7 bearish.
- XRAY’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а -4.23% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -2.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.10%. For the same industry, the average monthly price growth was +3.72%, and the average quarterly price growth was +23.35%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
XRAY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ALGN | XRAY | ALGN / XRAY | |
| Capitalization | 11.8B | 2.19B | 540% |
| EBITDA | 877M | -127M | -691% |
| Gain YTD | 5.418 | -4.549 | -119% |
| P/E Ratio | 27.67 | N/A | - |
| Revenue | 4.1B | 3.68B | 111% |
| Total Cash | 1.06B | 190M | 558% |
| Total Debt | 116M | 2.33B | 5% |
ALGN | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 67 | 97 | |
PRICE GROWTH RATING 1..100 | 58 | 64 | |
P/E GROWTH RATING 1..100 | 72 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (2) in the Medical Specialties industry is significantly better than the same rating for ALGN (78). This means that XRAY’s stock grew significantly faster than ALGN’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ALGN (100). This means that XRAY’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's SMR Rating (67) in the Medical Specialties industry is in the same range as XRAY (97). This means that ALGN’s stock grew similarly to XRAY’s over the last 12 months.
ALGN's Price Growth Rating (58) in the Medical Specialties industry is in the same range as XRAY (64). This means that ALGN’s stock grew similarly to XRAY’s over the last 12 months.
ALGN's P/E Growth Rating (72) in the Medical Specialties industry is in the same range as XRAY (82). This means that ALGN’s stock grew similarly to XRAY’s over the last 12 months.
| ALGN | XRAY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | N/A |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 74% |
| Advances ODDS (%) | 21 days ago 71% | 12 days ago 54% |
| Declines ODDS (%) | 8 days ago 73% | 6 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 62% |
Advertisement
ALGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with BAX. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then BAX could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | -2.47% | ||
| BAX - ALGN | 64% Loosely correlated | -2.56% | ||
| NVST - ALGN | 57% Loosely correlated | -0.17% | ||
| LUNG - ALGN | 52% Loosely correlated | +2.78% | ||
| XRAY - ALGN | 50% Loosely correlated | -0.82% | ||
| SAUHY - ALGN | 49% Loosely correlated | -1.02% | ||
More | ||||
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been closely correlated with NVST. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | -0.82% | ||
| NVST - XRAY | 67% Closely correlated | -0.17% | ||
| BLFS - XRAY | 50% Loosely correlated | -1.45% | ||
| QDEL - XRAY | 50% Loosely correlated | -7.78% | ||
| ALGN - XRAY | 50% Loosely correlated | -2.47% | ||
| KIDS - XRAY | 48% Loosely correlated | -3.43% | ||
More | ||||